Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Reports Rise in Q1 Revenues, Flat Losses

NEW YORK, April 24 - Illumina reported increased revenues for the first quarter late yesterday, amid nearly flat net losses.

 

The San Diegogenotyping and oligonucleotide company's revenues for the quarter ended March 30 totaled $4.3 million, up from $1.3 million for the first quarter of last year.

 

Research and development expenses decreased slightly, to $5.7 million, from $7.1 million in the same period last year.

 

The company's net losses totaled $9.0 million for the quarter, up a hair from the $8.7 million in net losses reported for the first quarter of 2002.

 

At the end of March, Illumina had $60.4 million in cash and investments, a slight decrease from the $66.3 million it reported at the same time last year.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.